FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin

Gastroenterology. 2014 Dec;147(6):1196-200. doi: 10.1053/j.gastro.2014.10.027. Epub 2014 Oct 27.

Authors

Affiliation

¹ US Food and Drug Administration, Silver Spring, Maryland.

PMID: 25449024
DOI: 10.1053/j.gastro.2014.10.027

No abstract available

Publication types

Comment

MeSH terms

Antiviral Agents / therapeutic use*
Drug Approval*
Hepatitis C, Chronic / drug therapy*
Humans
Sofosbuvir
Uridine Monophosphate / analogs & derivatives*
Uridine Monophosphate / therapeutic use

Substances

Antiviral Agents
Uridine Monophosphate
Sofosbuvir